Shopping Cart
Remove All
Your shopping cart is currently empty
Orotic acid monohydrate
Copy Product Info
😃Good
Catalog No. T5078Cas No. 50887-69-9
Alias Orotic Acid Monohydrate, 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate, 2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate
Orotic acid monohydrate is an intermediate product in pyrimidine metabolism.
Orotic acid monohydrate
Copy Product Info😃Good
Purity: 99.30%
Catalog No. T5078Alias Orotic Acid Monohydrate, 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate, 2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrateCas No. 50887-69-9
Orotic acid monohydrate is an intermediate product in pyrimidine metabolism.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 g | $29 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.30%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Orotic acid monohydrate is an intermediate product in pyrimidine metabolism. |
| In vitro | Orotic acid increases cell proliferation and decreases apoptosis in serum-starved SK-Hep1 hepatocellular carcinoma cells, which may ascribe to the inhibition of AMP-activated protein kinase (AMPK) phosphorylation and thus activation of mammalian target of rapamycin complex 1 (mTORC1) [1]. |
| In vivo | Male Fischer 344 rats (130-150 g) to two-thirds PH in the absence or in the presence of Orotic acid (a 300-mg tablet of Orotic acid methyl ester implanted intraperitoneally at the time of two-thirds PH). treatment with Orotic acid resulted in a near-100% inhibition of RNR induced by two-thirds PH in rat liver, as monitored by enzyme activity and protein level [2]. Feeding 1% Orotic acid with diet decreased the phosphorylation of AMPK and increased the maturation of SREBP-1 and the expression of SREBP-responsive genes in the rat liver. Orotic acid-induced lipid accumulation was also completely inhibited by rapamycin. Mouse hepatocytes and mice were resistant to Orotic acid-induced lipogenesis because of little if any response in AMPK and downstream effectors [3]. |
| Synonyms | Orotic Acid Monohydrate, 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate, 2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate |
| Molecular Weight | 174.11 |
| Formula | C5H6N2O5 |
| Cas No. | 50887-69-9 |
| Smiles | O.OC(=O)C1=CC(=O)NC(=O)N1 |
| Relative Density. | 1.642 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 2.5 mg/mL (14.36 mM), Sonication is recommended.  Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Orotic acid monohydrate | purchase Orotic acid monohydrate | Orotic acid monohydrate cost | order Orotic acid monohydrate | Orotic acid monohydrate chemical structure | Orotic acid monohydrate in vivo | Orotic acid monohydrate in vitro | Orotic acid monohydrate formula | Orotic acid monohydrate molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.